-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
What is the annual salary of foreign medical professionals? There is another data coming out this week.
According to statistics from the Korean Financial Supervisory Commission (FSS), the average annual salary of the management and employees of multinational pharmaceutical companies in South Korea was 91 million won (about 530,000 yuan) last year.
This data is obtained by the Korean Financial Supervisory Commission’s investigation of audit reports submitted by 24 multinational pharmaceutical companies in South Korea.
Statistics show that GlaxoSmithKline Korea Consumer Health Products Company ranked first with an average annual salary of 148 million won.
Before that, GlaxoSmithKline Korea had always been the company with the highest average salary of a multinational pharmaceutical company.
Other multinational pharmaceutical companies in Korea with an average annual salary of more than 100 million won include Boehringer Ingelheim (133 million won), Sanofi Pasteur (129 million won), Huizhi (126 million won), and Concord Kirin (1.
Among the 24 multinational pharmaceutical companies that submitted audit reports, 17 companies had an average annual salary of more than 80 million won.
However, because some companies include the salary of factory employees and R&D personnel as production costs and R&D expenses, the average salary obtained by the above method cannot reflect the real income of the employees of these companies, such as Janssen Korea.
But in general, the average salary of employees in Korean multinational pharmaceutical companies is much higher than that of Korean local pharmaceutical companies.